Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer

Lung cancer is a fatal disease with the highest worldwide morbidity and mortality rates. Despite recent advances in targeted therapy and immune checkpoint inhibitors for cancer, their efficacy remained limited. Therefore, we designed a Newcastle disease virus (NDV)‐modified tumor whole‐cell vaccine...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2023-02, Vol.95 (2), p.e28554-n/a
Main Authors: Wang, Hui, Nan, Fulong, Zeng, Zhou, Zhang, Xueming, Ke, Dingxin, Zhang, Shuyun, Zhou, Xiaoqiong, Niu, Delei, Fan, Tianyu, Jiang, Shasha, Zhang, Xianjuan, Wang, Yunyang, Wang, Bin, Zhang, Wanming
Format: Article
Language:English
Subjects:
Antigen presentation
Antigens
Antitumor activity
Cancer vaccines
Cell activation
Cell death
Cell differentiation
Combined vaccines
Dendritic cells
Immune checkpoint inhibitors
Immune response
Immune system
immunogenic cell death
Immunogenicity
Immunotherapy
immunotherapy of lung cancer
Inflammation
Injection
Lung cancer
Lymphocytes
Lymphocytes T
Metastases
Morbidity
Newcastle disease
Newcastle disease virus
T cell response
tumor cell vaccine
Tumors
Vaccines
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is a fatal disease with the highest worldwide morbidity and mortality rates. Despite recent advances in targeted therapy and immune checkpoint inhibitors for cancer, their efficacy remained limited. Therefore, we designed a Newcastle disease virus (NDV)‐modified tumor whole‐cell vaccine as a therapeutic vaccine and identified its antigen presentation level to develop effective immunotherapy. Then, we calculated the therapeutic and immune‐stimulating effects of NDV‐modified lung cancer cell vaccine and intratumoral NDV injection combination on tumor‐bearing mice. The results showed that the immunogenic cell death (ICD) expression in NDV‐modified lung cancer cell vaccine stimulates dendritic cell maturation and T cell activation in vivo and in vitro. Moreover, NDV‐modified lung cancer cell vaccine combined with intratumoral NDV injection could significantly inhibit tumor growth and enhance the differentiation of Th1 cells and Inflammatory cell infiltration in vivo, leading to an excellent immunotherapeutic effect. Therefore, our results revealed that NDV‐modified lung cancer cell vaccine combined with intratumoral NDV injection could promote antigen presentation and induce a strong antitumor immune response, which provided a promising combined therapy strategy for tumor immunotherapy.
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.28554